A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis.Consistent with the reports the panobinostat/ruxolitinib combination demonstrated the anticipated AEs but was considered tolerable in a small number of patients as showcased by those experiencing clinical benefits after ≥5 years of treatment
A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis / Harrison, Claire; Heidel, Florian H; Vannucchi, Alessandro M; Kiladjian, Jean-Jacques; Hayat, Amjad; Passamonti, Francesco; Conneally, Eibhlin; Kindler, Thomas; Martino, Bruno; Lipka, Daniel B; Stefanelli, Tommaso; Roussou, Pantelia; Germano, Davide; Ewan, Jacqueline; Ribrag, Vincent. - In: HEMASPHERE. - ISSN 2572-9241. - ELETTRONICO. - 6:(2022), pp. 1-4. [10.1097/HS9.0000000000000757]
A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis
Vannucchi, Alessandro MWriting – Original Draft Preparation
;
2022
Abstract
A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis.Consistent with the reports the panobinostat/ruxolitinib combination demonstrated the anticipated AEs but was considered tolerable in a small number of patients as showcased by those experiencing clinical benefits after ≥5 years of treatment
| File | Dimensione | Formato | |
|---|---|---|---|
|
hs9-6-e757.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
359.25 kB
Formato
Adobe PDF
|
359.25 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
